Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Intellia Therapeutics, Inc. (NTLA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress - Completed identification of all patients for the Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema - Plans to initiate a global pivotal Phase 3 study of NTLA-2002 as early as Q3 2024, subject to regulatory feedback - On track to submit IND application in September for a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedback - Plans to present additional clinical data in 2023 from the ongoing NTLA-2001 first-in-human study by year-end - Expects to submit a Clinical Trial Application by year-end for NTLA-3001, Intellia’s first in vivo inser..."
05/04/2023 8-K Quarterly results
Docs: "Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress - Dosed first patient in the global Phase 2 study of NTLA-2002 for the treatment of hereditary angioedema - Expects to complete enrollment in the Phase 2 study of NTLA-2002 in 2H 2023 - Plans to submit IND application in mid-2023 for a global pivotal study of NTLA-2001 for the treatment of transthyretin amyloidosis with cardiomyopathy; study initiation anticipated by year-end 2023, subject to regulatory feedback - On track to present additional clinical data in 2023 from both ongoing NTLA-2001 and NTLA-2002 first-in-human studies - Progressing next wave of clinical candidates, including NTLA-3001 and NTLA-2003, and advancing novel gene editing capabilities - Ended the first quarter o..."
08/04/2022 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Completed dose-escalation portion of the ongoing Phase 1study of NTLA-2001 in patients with transthyretin amyloidosis with cardiomyopathy; expects to present interim safety and serum TTR reduction data in 2H 2022 - Presented updated interim data from the dose-escalation portion of the polyneuropathy arm, establishing deep reductions of disease-causing protein were sustained through 12 months following a single dose of NTLA-2001 - Plans to present interim data for second in vivo CRISPR clinical candidate, NTLA-2002 for hereditary angioedema , in 2H 2022 - Moves to exclusively develop cell therapies leveraging its proprietary allogeneic platform; pivoting to an allogeneic version of..."
05/05/2022 8-K Quarterly results
11/04/2021 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Third Quarter 2021 Financial Results and Highlights Recent Company Progress - Initiated dosing of Cohort 4 in the ongoing Phase 1study of NTLA-2001; data update from completed dose-escalation and initiation of dose-expansion expected in Q1 2022 - Accelerated plans to evaluate NTLA-2001 for transthyretin amyloidosis with cardiomyopathy - On track to initiate first-in-human studies of NTLA-2002 for hereditary angioedema and NTLA-5001 for acute myeloid leukemia by year-end - Announces nomination of NTLA-3001, its first gene insertion development candidate, for alpha-1 antitrypsin deficiency ; concurrently, Regeneron and Intellia have selected a Factor 9 gene insertion development candidate to advance for hemophilia B - Presented new data on its proprietary and ..."
08/05/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "ATTR Program: Intellia recently announced the authorization of its Clinical Trial Application by the United Kingdom’s Medicines and Healthcare products Regulatory Agency to initiate a first-in-human clinical trial of NTLA-2001, an investigational therapy in development for the treatment of all clinical manifestations of ATTR. By applying the Company’s in vivo liver gene knockout technology, NTLA-2001 allows for the possibility of lifelong transthyretin protein reduction after a single course of treatment. Intellia’s first-in-human study will evaluate NTLA-2001 in adults with hereditary ATTR with polyneuropathy . The Phase 1study will be a two-part, open label, multi-center study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of NTLA-2001, which will include the m..."
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
10/31/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "SIGNATURE",
"Intellia Therapeutics Announces Second Quarter 2019 Financial Results and Company Update"
05/02/2019 8-K Quarterly results
Docs: "SIGNATURE",
"Intellia Therapeutics Announces First Quarter 2019 Financial Results and Company Update"
10/31/2018 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Third Quarter 2018 Financial Results and Corporate Developments"
08/01/2018 8-K Quarterly results
Docs: "Intellia Therapeutics Announces Second Quarter 2018 Financial Results"
05/01/2018 8-K Quarterly results
Docs: "Intellia Therapeutics Announces First Quarter 2018 Financial Results"
10/31/2017 8-K Quarterly results
08/01/2017 8-K Quarterly results
Docs: "FORM 8-K",
"Intellia Therapeutics Announces Second Quarter 2017 Financial Results"
05/02/2017 8-K Form 8-K - Current report
03/14/2017 8-K Form 8-K - Current report
11/01/2016 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy